Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis.

"Declarations Ethics approvalGiven the non-interventional retrospective nature of the study, no ethical approval for its conduct was necessary according to the policy of the ethics committee of the Faculty of Medicine of the University of Cologne. For the same reason, no informed consent had to be obtained from the included patients. Conflict of interestJGB received research funding and travel support from Kite/Gilead; BB received honoraria, research funding, or travel support from Astellas, Celgene, Janssen Cilag, Johnson & Johnson, Kite/Gilead, MSD, Noscendo, Novartis, Pfizer, Sanofi, and Takeda; MK received honoraria from Astellas, Gilead, MSD, and Pfizer; DAE received honoraria from Sanofi-Genzyme and Takeda; JMH received research funding or travel support from Gilead, Incyte, and Novartis; the other authors declare no potential conflicts of interest. Conflict of interest JGB received research funding and travel support from Kite/Gilead; BB received honoraria, research funding, or travel support from Astellas, Celgene, Janssen Cilag, Johnson & Johnson, Kite/Gilead, MSD, Noscendo, Novartis, Pfizer, Sanofi, and Takeda; MK received honoraria from Astellas, Gilead, MSD, and Pfizer; DAE received honoraria from Sanofi-Genzyme and Takeda; JMH received research funding or travel support from Gilead, Incyte, and Novartis; the other authors declare no potential conflicts of interest."

"Funding Open Access funding enabled and organized by Projekt DEAL."